Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Guisier

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2023
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world studyLionel Falchero, Florian Guisier, Marie Darrason, et al.
Therapeutic Advances in Medical Oncology|July 21, 2020
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" studyDominique Arpin, Marie-Christine Charpentier, Marie Bernardi, et al.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
The European Respiratory Journal|August 12, 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsMyriam Delaunay, Jacques Cadranel, Amélie Lusque, et al.
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Clinical Lung Cancer|July 2, 2020
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer PatientsElisa Gobbini, Anne Claire Toffart, Maurice Pérol, et al.
The European Respiratory Journal|March 3, 2022
Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trialFlorian Guisier, Gaëtan Deslee, Philippe Birembaut, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2019
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort StudyAlice Tison, Gilles Quéré, Laurent Misery, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2023
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world studyLionel Falchero, Florian Guisier, Marie Darrason, et al.
Therapeutic Advances in Medical Oncology|July 21, 2020
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" studyDominique Arpin, Marie-Christine Charpentier, Marie Bernardi, et al.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
The European Respiratory Journal|August 12, 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsMyriam Delaunay, Jacques Cadranel, Amélie Lusque, et al.
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Clinical Lung Cancer|July 2, 2020
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer PatientsElisa Gobbini, Anne Claire Toffart, Maurice Pérol, et al.
The European Respiratory Journal|March 3, 2022
Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trialFlorian Guisier, Gaëtan Deslee, Philippe Birembaut, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2019
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort StudyAlice Tison, Gilles Quéré, Laurent Misery, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Pageof 9